Mission
CAMD's mission is to improve human health and well-being by developing new technologies and methods to accelerate the development and review of medical products for neurodegenerative diseases.
Progress
Since February 2008, when CAMD launched initial activity in three major areas – data sharing, disease modeling, and biomarkers – it has already reached significant milestones. Click below for highlights of our progress in Alzheimer's and Parkinson's disease.
 |
 |
|---|
This material is based upon works supported by
Science Foundation Arizona under grant No. SRG 0335-08.
The opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the Science Foundation Arizona.
What's New
Parkinson's Disease Drug Development Milestone Achieved: Data Standard Now Available
C-Path Cosponsors Workshop on Combination Drug Development for Alzheimer's Disease
CAMD Participates in International Conferences
Alzheimer's Association International Conference
Read more
Clinical Trials in Alzheimer's Disease Conference
Read more
Alzheimer's Clinical Trial Data by Pharmaceutical Researchers